β-Blockers are widely utilized in various systemic disorders such as hypertension, heart failure, and tremors. Their dermatological effects have garnered increasing interest, particularly in treating vascular malformations (hemangiomas), tumors (Kaposi sarcoma, melanoma), wound healing, pyogenic granulomas, and erythematotelangiectatic rosacea. β-Blockers are also important in dermatology due to their potential adverse reactions. They can trigger or exacerbate conditions like psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhidrosis, and vitiligo. While β-blockers have demonstrated positive effects, it is crucial to consider their potential immunologic adverse reactions and the possibility of therapeutic approaches.
to produce potentially severe adverse effects, especially in predisposed areas or areas of \textit{locus minoris resistantiae} in the skin. Consequent upon review, potential alternatives have been proposed (4-10).

We believe this will be a useful complementary article to those works that have highlighted their usefulness (11). A variety of dermatoses may be caused or aggravated by \(\beta\)-blockers. These include psoriasis, lichen planus-like drug eruptions (LDE), contact dermatitis, anaphylaxis, Raynaud's disease, acrocyanosis, alopecia and hyperhidrosis.

2. Cutaneous side - effects of \(\beta\)-blockers

Keratinocytes possess adrenergic receptors, which have been reported as being exclusively of the \(\beta_2\)-subtype (12). \(\beta_2\)-adrenergic receptors are densest at the basal cells and decrease in number towards the stratum corneum, while intracellular calcium concentrations are lowest at the basal cells, increasing towards the stratum corneum thus correlating with keratinocyte differentiation (13).

\textbf{Psoriasis.} Drugs may influence the course of psoriasis in certain ways, including: i) Precipitation of psoriasis \textit{de novo} in predisposed individuals and in those with a family history; ii) exacerbation of pre-existing psoriasis lesions; iii) production of psoriatic lesions in clinically normal skin of patients with psoriasis; and iv) development of treatment-resistant psoriasis (11-13).

‘Psoriasiform drug disorder’ refers to a group of diseases, which mimick psoriasis at some point in their course; these psoriasiform reactions are elicited by inflammatory events leading to dysregulation of cytokines, growth factors and keratinocyte differentiation (14). True drug-induced psoriasis tends to occur in a \textit{de novo} fashion in patients without a family or prior history and may mimick pustular psoriasis, but without nail or joint involvement (15). Delayed-type hypersensitivity reaction, impaired lymphocyte transformation or alterations in cyclic adenosine monophosphate (cAMP) have been proposed (13-16). cAMP is an intracellular messenger, which brings about the stimulation of proteins for cellular differentiation and inhibition of proliferation (17). Biopsy specimens from \(\beta\)-blocker-induced (metoprolol and atenolol) eruptions are characterised by excessive degranulation of neutrophils in the dermis. Nonselective \(\beta\)-blockers (propranolol, nadolol and sotalol) were associated with excessive release of macrophage proteolytic enzymes (18). Metoprolol, nebivolol and bisoprolol are highly selective \(\beta_1\)-receptor blockers. Nebivolol brought about diminished proinflammatory gene expression in endothelial and vascular smooth muscle cells (19).

\textbf{Rheumatoid arthritis.} Autoimmune disorders may be associated with \(\beta_2\)-adrenergoreceptor dysfunction and examples include: rheumatoid arthritis or systemic lupus erythematosus (20). Modification of \(\beta_2\)-adrenergoreceptor structure could augment sensitivity levels of T-lymphocytes to \(\beta_2\)-stimulation. This could be a basis for the genetic predisposition to rheumatoid arthritis (21). One study involving murine cells demonstrated a bimodal activity of the sympathetic nervous system. There was proinflammatory activity during the asymptomatic phase and inhibitory activity during the chronic symptomatic phase of arthritis. This supported the idea that \(\beta_2\)-adrenergoreceptor stimulus is time-dependent and may play a role in the treatment of bone destruction in rheumatoid arthritis (22,23).

Thus, \(\beta_2\)-adrenergoreceptor activity is implicated in the generation, progression and treatment of rheumatoid arthritis, and this complex relationship has been mimicked by a variety of other autoimmune diseases, such as psoriasis or psoriatic arthropathy (24). A metoprolol-associated onset of psoriatic arthropathy has been described in a case report (25).

\textbf{Anaphylaxis.} Not surprisingly, as with any other drug, hypersensitivity reactions have occurred to \(\beta\)-blockers. Epinephrine-resistant anaphylaxis was reported in a patient taking propranolol 40 mg b.d. and intubation was necessary for successful recovery (26). The mechanism of action may in part be due to mast cell priming, which was noted with metoprolol and this augmenting effect was increased when metoprolol was combined with angiotensin converting enzyme inhibitor (ACE) (27).

\textbf{Periocular and ocular reactions.} Periorbital dermatitis and punctate keratitis, as well as conjunctival and eyelid symptoms were reported in patients on treatment with topical \(\beta\)-blockers over a 3-month survey period of ophthalmologists in The Netherlands (28). Periocular dermatitis was the most commonly encountered phenomenon and the most commonly encountered culprit was timolol.

One study compared \textit{in vitro} cytotoxicity, using the MTT assay, of 8 \(\beta\)-blockers (propranolol, alprenolol, atenolol, labetalol, metoprolol, pindolol, timolol and bisoprolol) on cell lines of the human corneal epithelium and retinal pigment epithelium. Primary and immortalised corneal and retinal cell lines were compared for susceptibility to the cytotoxic action of the drugs. \(\beta\)-Blocker cytotoxicity was also evaluated on human cutaneous keratinocytes and fibroblasts in order to assess susceptibility differences as a function of tissue of origin. Results demonstrated large variations in cytotoxicity (~60-fold) for these closely related drugs from the same cell line (29).

\textbf{Vitiligo.} Patients on systemic \(\beta\)-blocker therapy could suffer an exacerbation of their vitiligo. Accelerated deterioration of vitiligo lesions was observed in patients treated with \(\beta\)-blockers (30). Doppler flowmetry and iontophoresis showed increased blood flow in lesions of vitiligo as compared with normal skin, with a more marked increase in segmental vitiligo patients. Segmental vitiligo patients also had an increased density of \(\alpha\)- and \(\beta\)-adrenoceptors (31). This dysfunction of the sympathetic nervous system in the skin of vitiligo patients may provide a basis for the effect of \(\beta\)-blockers in the pathogenesis of vitiligo and caution should be exercised when vitiligo is part of one of the multiple autoimmune syndrome (vitiligo, lupus and thyroiditis) (32).

\textbf{Alopecia.} Alopecia has been described following topical timolol use in a patient with glaucoma (33). This manifested as telogen effluvium, which remitted following drug discontinuation and pretreatment hair volume was restored in 14 months. The patient also developed periocular contact dermatitis after the onset of alopecia. No mechanism was proposed for this
observation by the authors. Hair growth cycles have, however, been found to be modulated by adrenergic stimulation (34). Nonetheless, the simultaneous onset of contact dermatitis and alopecia, both autoimmune disorders suggests an autoimmune mechanism. Alopecia has long been recognized as an adverse effect of β-blockers and the suggested mechanism was described by Fraunfelder et al as ‘probably a direct toxic effect on the hair follicle’. They also discussed an impressive number of cases and reversibility after stopping the treatment (35-41).

Lichen planus-like drug eruption. Lichenoid drug eruptions may be associated with various β-adrenergic blocking agents (42,43). Histopathologic analysis has shown increased necrotic keratinocytes grouped in clusters, with increase in plasma cells and eosinophils being more associated with lichen planus-like drug eruption as opposed to lichen planus or other lichenoid disorders (44-47).

The first case in the literature describing lichenoid type cutaneous hyperpigmentation as a form of phototoxicity induced by nebivolol was reported in a 46-year-old female patient. In this case, alternative diagnoses, such as idiopathic lichen planus, systemic connective tissue disease, cutaneous forms of lupus erythematosus, lichenoid contact reaction, and hepatobiliary disease, could be excluded due to the history of the patient, clinical picture, biopsy findings, and time course of the skin lesions. Ultimately, it was concluded that nebivolol may cause lichenoid cutaneous hyperpigmentation. Therefore, in patients using nebivolol, this side effect should be kept in mind (48).

Hyperhidrosis. Hyperhidrosis has been reported in association with β-adrenoceptor blockade. Axillary area appears to be the most affected (49). It is not clear whether there is an underlying immune mechanism. Mechanisms based on receptor changes or mediator imbalances (as both cholinergic and adrenergic pathways seem to be involved in sweating) are more likely than autoimmune mechanisms (50). The fact that ‘diabetics who become hypoglycemic actually sweat more on propranolol as compared with those who are not on propranolol’, may also be relevant in building a working hypothesis (51).

Contact dermatitis. Occupational contact dermatitis was noted in a 48-year-old male worker in a pharmaceutical factory. This affected the patient's hands and the agent was determined to be propranolol after patch testing (52). The patient improved after he was moved to a different department. Allergic contact dermatitis to β-adrenergic agents in eye drops has been reported. It is unusual, but timolol was considered by far the greatest culprit (53). The treatment for contact dermatitis to β-adrenergic agents is topical steroids, which are also known for their own cutaneous adverse reactions (54-57).

β-Blockers have been successfully used in dermatoses such as hemangiomas, kaposiform haemangioendothelioma, pyogenic granulomas, erythematito-telangiectatic rosacea, angiolymphoid hyperplasia with eosinphillia. There have been promising results in adrenergic urticaria, aquagenic pruritus, wound healing, pemphigus vulgaris, other autoimmune blistering diseases and potentially in melanoma (58,59).

Other immunological and some non-immunological adverse cutaneous drug reactions of β-blockers are included in Table I: for atenolol-vasculitis (V), drug-induced lupus erythematosus (DILE), pseudolymphomatous reactions (PR); for acebutolol-lichenoid reactions (LR), DILE, pincer nail deformity (PND); for metoprolol-PND, PD; for propranolol-erythema multiforme, alopecia, PD, LR; for pindolol-LR, DILE; for oxprenolol-ocularcutaneous syndrome, LR, DILE; for sotalol-V (60-63).

3. Conclusion

This summary review has delved into the immunologic side-effects of β-blockers. These should be borne in mind by dermatologists, cardiologyists, ophthalmologists, neurologists, pediatricians, internists, family physicians and other specialists that prescribe this category of drugs.

With regard to medical ethics, it may be useful, prior to the prescription and administration of β-blockers to inform our patients of the possible adverse reactions and making them sign an informed consent form (64,65). In the future, in order to obviate such potential risks perhaps plant extracts with limited potential for adverse reactions and benign alternative treatments could be investigated and utilised (66,67), especially as knowledge removes discomfort (68,69).

Acknowledgements

Not applicable.
Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors’ contributions

ALT, VC, MM contributed to the conception, design, and drafting the study. AME and LCN contributed to the interpretation of the data, and revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript and contributed equally in all the stages of the study. They reached an agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Akbar S and Alorainy MS: The current status of β-blockers’ use in the management of hypertension. Saudi Med J 35: 1307-1317, 2014.
2. Pemberton P, Veenith T, Snelson C and Whitehouse T: Is it time to beta block the septic patient? Biomed Res Int 2015: 424308, 2015.
3. Loftus TJ, Efrom PA, Moldawer LL and Mohr AM: β-blockade for traumatic injuries and immunomodulation: A review of proposed mechanisms and clinical evidence. Shock 46: 341-351, 2016.
4. Nwabudike LC and Tatu AL: Response to chronic exposure to tetracyclines and subsequent diagnosis for non-melanoma skin cancer in a large Mid-Western US population. J Eur Acad Dermatol Venereol 32: e159, 2018.
5. Tatu AL and Nwabudike LC: Bullous reactions associated with COX-2 inhibitors. Am J Ther 24: e477-e480, 2017.
6. Gheorghe I, Tatu AL, Lupu I, Thamer O, Cotar AI, Pircalabioru GG, Popa M, Cristea VC, Lazar V and Chiﬁriuc MC: Molecular characterization of virulence and resistance features in Staphylococcus aureus clinical strains isolated from cutaneous lesions in patients with drug adverse reactions. Rom Biotechnol Lett 22: 12321-12327, 2017.
7. Happle R and Kluger N: Koebner’s sheep in Wolf’s clothing: An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum 52: 1305-1313, 2005.
8. Fan X and Wang L: Adrenergic receptors on T lymphocytes and its clinical implications. Prog Nat Sci 19: 17-23, 2009.
9. Tatu AL and Nwabudike LC: Metoprolol-associated onset of psoriatic arthropathy. Am J Ther 24: e370-e371, 2017.
10. Newman BR and Schultz LK: Epinephrine-resistant anaphylaxis in a patient taking propanolol hydrochloride. Ann Allergy 47: 35-37, 1981.
11. Narsiri M, Babina M, Dülle S, Edenharter G, Ruffe F and Worm M: Ramipril and metoprolol intake aggravate human and murine anaphylaxis: Evidence for direct mast cell priming. J Allergy Clin Immunol 135: 491-499, 2015.
12. van Beek LM, de Keizer RJ, Polak BCP, Elzenaar PR, van Haeringen NJ and Kijlstra A: Incidence of ocular side effects post β-blockers in the Netherlands. Br J Ophthalmol 84: 856-859, 2000.
13. Cheong HI, Johnson J, Cormier M and Hosseini K: In vitro cytotoxicity of eight β-blockers in human corneal epithelial and retinal pigment epithelial cell lines: Comparison with keratinocytes and dermal fibroblasts. Toxicol In Vitro 22: 1070-1076, 2008.
14. Schallreuter KU: Beta-adrenergic blocking drugs may exacerbate vitiligo. Br J Dermatol 132: 168-169, 1995.
15. Wu CS, Yu HS, Chang HR, Yu CL, Yu CL and Wu BN: Cutaneous blood flow and adrenergic response increase in segmental-type vitiligo lesions. J Dermatol Sci 23: 53-62, 2000.
16. Tatu AL and Ionescu MA: Multiple autoimmune syndrome type III-thyroiditis, vitiligo and alopecia areata. Acta Endo Hokkaido 13: 124-125, 2017.
17. Muramatsu K, Nomura T, Shiyai C, Niishiura K and Tsukinaga I: Alopecia induced by timolol eye-drops. Acta Derm Venerol 97: 295-296, 2017.
18. Bottchkareva VA, Peters EM, Bottchkareva NV, Maurer M and Luger T: Hair cycle-dependent changes in adrenergic skin innervation, and hair growth modulation by adrenergic drugs. J Invest Dermatol 113: 878-887, 1999.
35. Lewis RV and Lofthouse C: Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf 9: 272-279, 1993.
36. Fraunfelder FT, Meyer SM and Menacker SJ: Alopexia possibly secondary to topical ophthalmic β-blockers. JAMA 263: 1493-1494, 1990.
37. Richards S: Cutaneous side-effects of beta-adrenergic blockers. Australas J Dermatol 26: 25-28, 1985.
38. Shelley ED and Shelley WB: Alopecia and drug eruption of the scalp associated with a new beta-blocker, nadolol. Cutis 35: 148-149, 1985.
39. England JR and England JD: Alopecia and propranolol therapy. Aust Fam Physician 11: 225-226, 1982.
40. Hilder RJ: Propranolol and alopecia. Cuts 24: 63-64, 1979.
41. Martin CM, Southwick EG and Maibach HI: Propranolol induced alopecia. Am Heart J 86: 236-237, 1973.
42. Bodmer M, Egger SS, Hohenstein E, Beltraminelli H and Krähenbühl S: Lichenoid eruption associated with the use of nebivolol. Ann Pharmacother 40: 1688-1690, 2006.
43. Meyer S, Burgdorf T, Szeitlies RM, Vogt T, Landthaler M and Karrer S: Management of erosive lichen planus with topical tacrolimus and recurrence secondary to metoprolol. J Eur Acad Dermatol Venereol 19: 236-239, 2005.
44. Brănişteanu DE, Pintilie A and Dimitriu A, Cerbu A, Ciobanu D, Brănişteanu DE, Pintilie A and Dimitriu A: Histopathological and clinical traps in lichen planus: A case report. Rom J Morphol Embryol 51: 1199-1205, 2012.
45. Lage D, Juliano PB, Metze K, de Souza EM and Cintra ML: Lichen planus and lichenoid drug-induced eruption: A histological and immunohistochemical study. Int J Dermatol 51: 69-73, 2012.
46. Tatu AL, Clătici V: Some correlations between the clinical and dermoscopic features of steroid induced facial dermatitis. J Am Acad Dermatol 72: 91, 2015.
47. Miyamoto D, Maruta CW, Santi CG, Zoroquiain P, Dias AB, Mansure J Jr, Burnier MN Jr and Aoki V: Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceae variants and pemphigus vulgaris. J Eur Acad Dermatol Venereol: Feb 28, 2018 (Epub ahead of print). doi: 10.1111/jdv.14903.
48. Abdelmakssoud A and Vestita M: Beta-blockers for treatment of autoimmune blistering dermatosis. J Eur Acad Dermatol Venereol: May 6, 2018 (Epub ahead of print). doi: 10.1111/jdv.15054.
49. Prabha N, Chhabra N and Arora R: Beta-blockers in dermatology. Indian J Dermatol Venereol Leprol 83: 399-407, 2017.
50. mamu P and Rogozea LM: Propranolol for angina pectoris. Am J Ther 23: e1285-e1286, 2016.
51. Biliewicz-Stebel M, Miziolek B, Bergler-Czob B and Staňkovska A: Drug-induced subacute cutaneous lupus erythematosus caused by a topical beta blocker - timolol. Acta Dermato-Venereol 26: 44-47, 2018.
52. Pulitzer MP, Nolan KA, Oshman RG and Phelps RG: CD30+ lymphomatoid drug reactions. Am J Dermatopathol 35: 343-350, 2013.
53. Rogozea LM, Diaconescu DE, Dinu EA, Badea O, Popa D, Andreescu Ť and Leașu FG: Bioethical dilemmas in using animal in medical research. Challenges and opportunities. Rom J Morphol Embryol 56: 1227-1231, 2015.
54. Purcaru D, Preda A, Popa D, Moga MA and Rogozea L: Informed consent: How much awareness is there? PLoS One 9: e101399, 2014.
55. Dumitriu BO, Fasie V, Mardare N, Diaconu C and Guran G and Dumitriu BO, Fasie V: Formulation, preparation, physico-chemical analysis, microbiological peculiarities and therapeutic challenges of extractive solution of Kombucha. Rev Chim (Bucharest) 69: 720-724, 2018.
56. Robu S, Chesaru BI, Diaconu C, Dumitriu BO, Tutunaru D, Stanescu U and Lisa EL: Lavandula hybrida: Microbiological characterization and the evaluation of the essential oil. Farmacia 64: 914-917, 2016.
57. Nwabudike LC: Case reports of acne and homeopathy. Complement Med Res 25: 52-55, 2018.
58. Nwabudike LC: Knowledge removes discomfort. JAMA Dermatol 154: 738-739, 2018.